83 unknown. 83 Phase 2, 40 Phase 1, 6 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 83 | Unknown 83 |
| Phase 1 | 40 | Unknown 40 |
| Phase 3 | 6 | Unknown 6 |
Follow Acute Myeloid Leukemia: new trials by email Literature Review of Acute Myeloid Leukemia trials Research Report on Acute Myeloid Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of TQB3454 Tablets in Patients With Blood Tumors TQB3454 Tablets - Acute Myeloid Leukemia, Myelodysplastic Syndromes | Phase 1 / Phase 2 | Unknown | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 80 | 2023-07-10 | 2024-01-23 |
| RC1012 Injection (Allo-DNT Cells) for the Prevention of Relapse in AML Patients After Allo-HSCT RC1012 injection (allo-DNT cells) - Acute Myeloid Leukemia | Phase 1 / Phase 2 | Unknown | Guangdong Ruishun Biotech Co., Ltd | 72 | 2023-05-04 | 2023-05-19 |
| A Study on the Efficacy and Safety of Venetoclax Combined With HAA Regimen in Newly Diagnosed Young AML. combination of venetoclax and HAA regimen - Acute Myeloid Leukemia, Venetoclax | Phase 1 / Phase 2 | Unknown | ZePing Zhou | 45 | 2023-04-01 | 2023-06-08 |
| Safety and Efficacy of Venetoclax in Combination With Azacitidine and HA Regimen in the Treatment of AML in the Elderly Venetoclax in Combination With Azacitidine and HA Regimen - Acute Myeloid Leukemia | Phase 1 / Phase 2 | Unknown | ZePing Zhou | 45 | 2023-04-01 | 2023-07-18 |
| Clinical Study of Venetoclax Combined With CAG in the Treatment of Refractory/Relapsed Acute Myeloid Leukemia Ven+CAG - Acute Myeloid Leukemia | Phase 2 | Unknown | Peking University People's Hospital | 52 | 2023-02-01 | 2023-11-21 |
| Evaluation of the Safety and Efficacy of Esperanza Extract (PA001) Petiveria Alliacea Preparation, Placebo - Neoplasm, Stomach, Gastric Neoplasms Malignant | Phase 1 / Phase 2 | Unknown | Hospital Universitario San Ignacio | 82 | 2022-12-15 | 2022-10-19 |
| A Clinical Study of 6MW3211 Monotherapy or Combination Therapy for AML or MDS 6MW3211 injection with Intravenous Infusion - Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 1 / Phase 2 | Unknown | Mabwell (Shanghai) Bioscience Co., Ltd. | 120 | 2022-07-08 | 2023-03-15 |
| Venetoclax and Azacitidine for the Management of Molecular Relapse/Progression in Adult NPM1-mutated Acute Myeloid Leukemia Venetoclax+azacitidine - Acute Myeloid Leukemia, Acute Myeloid Leukemia, in Relapse | Phase 2 | Unknown | Gruppo Italiano Malattie EMatologiche dell'Adulto | 35 | 2022-03-01 | 2022-03-16 |
| Venetoclax+Azacytidine+Modified BUCY Conditioning Regimen for Acute Myeloid Leukemia and Myelodysplastic Syndromes Undergoing Allo-HSCT VEN+AZA+Modified BUCY - Allogeneic Hematopoietic Stem Cell Transplantation, Acute Myeloid Leukemia | Phase 2 | Unknown | The First Affiliated Hospital of Soochow University | 70 | 2022-01-20 | 2023-04-21 |
| A Study of IMM01 Combined With Azacitidine in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome IMM01, Azacitidine - Acute Myeloid Leukemia, Myelodysplastic Syndromes | Phase 1 / Phase 2 | Unknown | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | 126 | 2022-01-05 | 2023-05-24 |
| Anti-FLT3 CAR T-cell Therapy in FLT3 Positive Relapsed/Refractory Acute Myeloid Leukemia anti-FLT3 CAR-T - Acute Myeloid Leukemia | Phase 1 / Phase 2 | Unknown | The First Affiliated Hospital of Soochow University | 5 | 2021-12-31 | 2021-12-30 |
| A Study to Evaluate the Safety and Tolerance of SYHX1903 in Patients With Relapsed/Refractory Hematologic Malignancies SYHX1903 - Acute Myeloid Leukemia, Lymphoma | Phase 1 / Phase 2 | Unknown | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 312 | 2021-12-29 | 2021-09-24 |
| Expanded Haploidentical Natural Killer Cells as Consolidation Strategy for Children/Young Adults With AML Expanded haploidentical NK cells - Acute Myeloid Leukemia | Phase 1 / Phase 2 | Unknown | Belarusian Research Center for Pediatric Oncology, Hematology and Immunology | 15 | 2021-11-01 | 2024-08-28 |
| Immunotherapy With ex Vivo Expanded Haploidentical Natural Killer Cells for Children/Young Adults With AML NK cell infusions - Acute Myeloid Leukemia | Phase 1 / Phase 2 | Unknown | Belarusian Research Center for Pediatric Oncology, Hematology and Immunology | 15 | 2021-11-01 | 2024-08-28 |
| A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Max-40279-01 in Combination With Azacitidine (AZA) in Patients With Myelodysplastic Syndrome (MDS) or Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) MAX-40279-01 - Leukemia, Acute Myeloid Leukemia | Phase 1 / Phase 2 | Unknown | Maxinovel Pty., Ltd. | 100 | 2021-09-16 | 2021-10-01 |
| Ex-vivo Primed Memory Donor Lymphocyte Infusion to Boost Anti-viral Immunity After T-cell Depleted HSCT boost anti-viral immunity after T-cell depleted HSCT - Acute Myeloid Leukemia, High Risk Acute Myeloid Leukemia | Phase 1 / Phase 2 | Unknown | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | 20 | 2021-09-16 | 2021-10-04 |
| Safety and Efficiency of γδ T Cell Against Hematological Malignancies After Allo-HSCT Ex-vivo expanded γδ T cell infusion - Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Unknown | Chinese PLA General Hospital | 20 | 2021-09-12 | 2022-03-28 |
| Humanized CD7 CAR T-cell Therapy for r/r CD7+ Acute Leukemia Humanized CD7 CAR-T cells - T Lymphoblastic Leukemia/Lymphoma, Mixed Phenotype Acute Leukemia | Phase 1 / Phase 2 | Unknown | The First Affiliated Hospital of Soochow University | 20 | 2021-06-01 | 2021-06-02 |
| Study of Chidamide Combined With Cladribine in Refractory/Relapsed Acute Myeloid Leukemia Chidamide, Cladribine - Acute Myeloid Leukemia | Phase 2 | Unknown | Ge Zheng | 31 | 2021-06-01 | 2022-04-29 |
| Relatlimab With Nivolumab and 5-Azacytidine for the Treatment of AML Azacitidine Injection, Nivolumab, Relatlimab - Acute Myeloid Leukemia | Phase 2 | Unknown | Ludwig-Maximilians - University of Munich | 30 | 2021-05-05 | 2022-11-08 |
Showing 20 of 83. Sign in to see all of them.
Leukemia, Myeloid, Acute (83) · Myelodysplastic Syndromes (21) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (8) · Recurrence (5) · Leukemia (4) · Lymphoma (4) · Leukemia, Myelomonocytic, Chronic (3) · Lymphoma, Non-Hodgkin (3) · Multiple Myeloma (3) · Leukemia, Biphenotypic, Acute (2) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (2) · Anemia, Aplastic (1) · Colorectal Neoplasms (1) · Enteropathy-Associated T-Cell Lymphoma (1) · Hematologic Neoplasms (1)
Hematologic Diseases (83) · Hemic and Lymphatic Diseases (83) · Leukemia, Myeloid (83) · Neoplasms by Histologic Type (83) · Neoplasms (82) · Leukemia (79) · Bone Marrow Diseases (22) · Immune System Diseases (12) · Immunoproliferative Disorders (12) · Lymphatic Diseases (12) · Lymphoproliferative Disorders (12) · Pathologic Processes (12) · Pathological Conditions, Signs and Symptoms (12) · Disease Attributes (11) · Leukemia, Lymphoid (11)
Cytarabine (15) · Azacitidine (9) · Decitabine (8) · Granulocyte Colony-Stimulating Factor (4) · Idarubicin (4) · fludarabine (4) · venetoclax (4) · Aclarubicin (3) · Busulfan (3) · Cladribine (3) · Clofarabine (2) · Filgrastim (2) · Sensitivity and Specificity (2) · 4-fluorobenzoyl-TN-14003 (1) · Antimony Sodium Gluconate (1)
The First Affiliated Hospital of Soochow University (6) · Nanfang Hospital, Southern Medical University (4) · Cooperative Study Group A for Hematology (3) · Belarusian Research Center for Pediatric Oncology, Hematology and Immunology (2) · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (2) · Ge Zheng (2) · Groupe Francophone des Myelodysplasies (2) · Hannover Medical School (2) · PersonGen BioTherapeutics (Suzhou) Co., Ltd. (2) · Sun Yat-sen University (2) · ZePing Zhou (2) · Actinium Pharmaceuticals (1) · Antisoma Research (1) · Ascentage Pharma Group Inc. (1) · Bayside Health (1)
China (33) · Germany (13) · United States (9) · South Korea (6) · France (4) · Italy (4) · Australia (2) · Belarus (2) · Brazil (2) · Hong Kong (2) · Spain (2) · Austria (1) · Belgium (1) · Colombia (1) · Georgia (1)
Xiaowen Tang, Ph.D (3) · Hawk Kim, professor (2) · Junmin Li (2) · Olga Aleinikova, MD, Prof (2) · Qifa Liu (2) · Zheng Ge, M.D, Ph.D (2) · Amit Verma, MD (1) · Andrea Velardi, MD, PhD (1) · Anskar Leung (1) · Anskar Leung, Professor (1) · Anthony P Schwarer, MB, BS, FRACP, MD, FRCPA (1) · Arnold Ganser, Prof. Dr. (1) · Avinash Desai, MD (1) · C. Orla Morrissey, MB, BCh, FRACP (1)
PMID 28054442, PMID 14603333, PMID 16564913, PMID 20371346, PMID 20959411, PMID 22589701, PMID 24497570, PMID 24641416, PMID 25621950, PMID 25631767, PMID 25805929, PMID 25891993, PMID 25983002, PMID 27347147, PMID 27716819, PMID 27916294, PMID 28034993, PMID 28161329, PMID 28412099, PMID 28415728, PMID 29506548, PMID 31409768, PMID 31432232, PMID 31739095, PMID 31819192, PMID 32711004, PMID 33184339, PMID 33347715, PMID 33462499, PMID 33646302, PMID 34034795, PMID 35417717, PMID 35582564, PMID 36175988, PMID 36399194, PMID 36524116, PMID 36568250, PMID 37226312, PMID 37563608, PMID 38304826, PMID 38467031, PMID 40831735, PMID 41980027, PMID 42374628
2019 (1)